Day: September 23, 2021

Please be informed that the Board of the Warsaw Stock Exchange (hereinafter, the “WSE”), taking into consideration the announced tender offer to subscribe for the sale of shares of AUGA group AB, code 126264360, address of the registered office Konstitucijos pr. 21C, Vilnius, Republic of Lithuania (hereinafter, the “Company”), in order to delist the Company’s shares from trading on the WSE, which was announced by Baltic Champs Group, UAB and in order to ensure proper execution of this tender offer, has adopted a decision to suspend trading of the Company’s shares on the WSE from 23 September 2021 (inclusive and from the beginning of the trading session) for an indefinite period. The Company notes that trading of the Company’s shares on the WSE was also suspended by the Board of WSE on 22 September 2021 from 10:49:00 CET until the...

Pratteln, Switzerland, and Rockville, MD, USA, September 23, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) announce presentations of the positive topline results from the pivotal VISION-DMD study and new safety analyses from long-term treatment with vamorolone at the forthcoming World Muscle Society (WMS) 2021 Virtual Annual Conference and The American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting. Recently, Santhera and ReveraGen announced statistically highly significant and clinically relevant data from the pivotal Phase 2b VISION-DMD study in patients with Duchenne muscular dystrophy (DMD) [1-3]. In the first 24-week phase of this trial, vamorolone demonstrated statistically significant and clinically relevant improvements versus placebo across five functional outcome measures...

MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) — Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:Total number of shares outstanding: 79,294,402 ordinary shares  6,784 Preferred Shares 2016  7,581 Preferred Shares 2017Total number of theoretical voting rights (1): 80,087,342Total number of exercisable voting rights (2): 80,068,767(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In...

Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) — Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:  Total number of shares outstanding: 79,294,402 ordinary shares  6,784 Preferred Shares 2016 7,581 Preferred Shares 2017Total number of theoretical voting rights (1): Total number of exercisable voting rights (2): 80,087,342 80,068,767  (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance...

Brings >25 years of executive financial leadershipLiège, Belgium – 23 September 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Jean-Luc Vandebroek will be joining the Company as its Chief Financial Officer. In addition to his new role at Hyloris, Jean-Luc will remain Non-Executive Director of the Board of Bone Therapeutics during a transition period to lead a managed succession. Jean-Luc will report to Hyloris’ CEO, and previously acting interim CFO, Stijn Van Rompay. Jean-Luc Vandebroek is a seasoned executive who most recently served as CFO of Bone Therapeutics, a publicly traded biotech company based in Gosselies, Belgium. Prior to that, he was CFO and CIO at Alcopa and Fluxys, and...

PRESS RELEASE: 23 September 2021, 07:00 CEST Biocartis Announces Restart of its High-Throughput Cartridge Manufacturing Line Mechelen, Belgium, 23 September 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the restart of its high-throughput ‘ML2’ cartridge manufacturing line. Following a fire that broke out at one of the Company’s warehouse facilities in Mechelen (Belgium) during the night of 30 July 2021, production at the ML2 line was temporarily suspended due to the need for structural repairs to the building and select supporting systems. Those repairs, as well as several subsequent control and quality related procedures, were completed earlier this week. This led to the successful restart of the ML2 line in the night of 21 September 2021. Herman...

Beter Bed Holding N.V. (BBH) – The Netherlands’ largest sleep specialist in retail, wholesale and B2B – launches five building blocks for the online strategy. This strategy will allow BBH to fulfil its ambition to achieve online sales of at least €100 million by 2025. The online strategy is part of a large number of initiatives launched by BBH over the last 12 months to achieve its medium-term ambitions. The online strategy is based on the following pillars:Launching digital organisation LUNEXT. Further professionalising and expanding the E-commerce department. Establishing Data & Analytics department. Opening of first e-DC of 11,000 m2 in October 2021. Broadening and deepening online categories.John Kruijssen, CEO of BBH, comments: “Our strategic ambition is to grow our online sales to at least €100 million in sales...